ApprovedFDA approval

Hovilpri (pritelivir)

AiCuris Anti-infective Cures

Marketer take

A niche launch for refractory HSV in immunocompromised adults, so transplant and oncology-center ID specialists and hospital formulary committees are the core audience.

Sponsor company
AiCuris Anti-infective Cures
Indication
To treat adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus infection and have not responded to other therapies
Therapeutic area
Infectious disease
Event
FDA approval
Date
Oct 9, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move